AQR Capital Management
SKYE icon

AQR Capital Management’s Skye Bioscience SKYE Stock Holding History

AQR Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,642
Closed -$122K – 3624
2025
Q2 		$122K Buy
3,642
+2,236
+159% +$37K ﹤0.01% 3146
2025
Q1 		$17.9K Sell
1,406
-1,301
-48% -$28.4K ﹤0.01% 3132
2024
Q4 		$61.3K Buy
+2,707
New +$90.5K ﹤0.01% 2798

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management's SKYE Position: Q3 2025 in Review

AQR Capital Management sold out of Skye Bioscience (SKYE) in Q3 2025, closing a stake of 3,642 shares — an estimated $122K sold.

AQR Capital Management first reported a position in SKYE in Q4 2024 and held it in 3 quarters. The position peaked at $122K in Q2 2025. 52 funds tracked by Wall St. Rank hold SKYE as of Q3 2025.

  • AQR Capital Management reported no remaining Skye Bioscience position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 3,642 Skye Bioscience shares in Q3 2025, an estimated $122K.
  • AQR Capital Management first reported a position in Skye Bioscience in Q4 2024 and held it in 3 quarters.
  • AQR Capital Management's Skye Bioscience position peaked at $122K in Q2 2025.
  • 52 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.